GBM remains the most lethal brain cancer with no effective therapeutics. It has been shown that the majority of stromal cells in GBM are tumor-associated macrophages (TAMs), which contribute to tumor microenvironment heterogeneity and promote GBM progression. We have recently defined molecular pathways leading to macrophage recruitment and polarization. Our preliminary data showed that PTEN mutation/deletion in GBM triggers immune response by enhancing macrophage recruitment through LOX. In addition, we have also identified TBK1 as a key signaling node regulating macrophage polarization.
Aim 1 : we will elucidate the mechanism of LOX mediated macrophage recruitment in GBM;
Aim 2 : we will determine the molecular basis of TBK1 mediated macrophage polarization in GBM;
Aim 3 : we will perform preclinical trials targeting LOX and TBK1 in combination with standard of care and immune checkpoint blockade to develop novel therapeutic approach for GBM patients.
s GBM is heavily infiltrated by tumor promoting macrophage through mechanisms still poorly understood. We have now identified two key therapeutic targets (LOX and TBK1) involved in macrophage recruitment and polarization, respectively, and preclinical therapeutic trials will be performed following detailed mechanistic characterization of novel LOX and TBK1 pathways.
